Benchmark lowered the firm’s price target on Humacyte (HUMA) to $14 from $17 and keeps a Buy rating on the shares. Humacyte launched Symvess in February and generated its first commercial product revenue during Q1, notes the analyst, who believes the company is poised to gain significant share for surgical procedures requiring vascular grafts and notes that the new product pipeline continues to move forward.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte’s Promising Growth: Strong Financials and Successful Symvess Launch Drive Buy Rating
- Humacyte Reports Q1 2025 Earnings and Strategic Progress
- Positive Momentum and Financial Stability Drive Buy Recommendation for Humacyte
- Humacyte reports Q1 EPS 28c, consensus (21c)
- Largest borrow rate increases among liquid names